|Bid||15.65 x 1200|
|Ask||15.78 x 1000|
|Day's Range||15.73 - 16.80|
|52 Week Range||2.50 - 35.10|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 20, 2017|
|1y Target Est||41.83|
Altimmune, Inc. ( NASDAQ:ALT ) is possibly approaching a major achievement in its business, so we would like to shine...
The COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE has proved to be as effective in the real world as it was in clinical trials in the first major study of the two-dose regiment involving 1.2 million people in Israel.
Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine. The study is expected to enroll up to 180 healthy adults between the ages of 18 and 55 years old, who will receive one of three doses of the experimental vaccine. The company said it expects to share the first batch of clinical data from this trial in the second quarter of this year. Altimmune's stock has soared 969.9% over the past 12 months, while the broader S&P 500 is up 21.7%.